Document Type

Article

Publication Date

2-1-2016

Identifier

PMCID: PMC4753865 DOI: 10.1097/MD.0000000000002473

Abstract

One of the main concerns in psychiatric care is safety related to drug management. Pharmacogenetics provides an important tool to assess causes that may have contributed the adverse events during psychiatric therapy. This study illustrates the potential of pharmacogenetics to identify those patients for which pharmacogenetic-guided therapy could be appropriate. It aimed to investigate CYP2D6 genotype in our psychiatric population to assess the value of introducing pharmacogenetics as a primary improvement for predicting side effects.A broad series of 224 psychiatric patients comprising psychotic disorders, depressive disturbances, bipolar disorders, and anxiety disorders was included. The patients were genotyped with the AmpliChip CYP450 Test to analyzing 33 allelic variants of the CYP2D6 gene.All bipolar patients with poor metabolizer status showed maniac switching when CYP2D6 substrates such as selective serotonin reuptake inhibitors were prescribed. No specific patterns were identified for adverse events for other disorders.We propose to utilize pharmacogenetic testing as an intervention to aid in the identification of patients who are at risk of developing affective switching in bipolar disorder treated with selective serotonin reuptake inhibitors, CYP2D6 substrates, and inhibitors.

Journal Title

Medicine

Volume

95

Issue

6

First Page

2473

Last Page

2473

MeSH Keywords

Antidepressive Agents, Second-Generation; Bipolar Disorder; Cytochrome P-450 CYP2D6; Genetic Markers; Genotype; Humans; Patient Safety; Quality Improvement; Serotonin Uptake Inhibitors; Treatment Outcome

Keywords

Manic Depressive

Download

Share

COinS